JP2015078199A5 - - Google Patents

Download PDF

Info

Publication number
JP2015078199A5
JP2015078199A5 JP2014231450A JP2014231450A JP2015078199A5 JP 2015078199 A5 JP2015078199 A5 JP 2015078199A5 JP 2014231450 A JP2014231450 A JP 2014231450A JP 2014231450 A JP2014231450 A JP 2014231450A JP 2015078199 A5 JP2015078199 A5 JP 2015078199A5
Authority
JP
Japan
Prior art keywords
cancer
diseases
mek
heptane
ethyl acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014231450A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015078199A (ja
JP6309880B2 (ja
Filing date
Publication date
Priority claimed from US11/830,733 external-priority patent/US8101799B2/en
Application filed filed Critical
Publication of JP2015078199A publication Critical patent/JP2015078199A/ja
Publication of JP2015078199A5 publication Critical patent/JP2015078199A5/ja
Application granted granted Critical
Publication of JP6309880B2 publication Critical patent/JP6309880B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

JP2014231450A 2007-07-30 2014-11-14 Ｍｅｋの阻害剤としての多形体を含む、ｎ−（アリールアミノ）スルホンアミドの誘導体、および組成物、使用方法、ならびにその調製方法 Expired - Fee Related JP6309880B2 (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US11/830,733 US8101799B2 (en) 2005-07-21 2007-07-30 Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
US11/830,733 2007-07-30
US3446608P 2008-03-06 2008-03-06
US3446408P 2008-03-06 2008-03-06
US61/034,466 2008-03-06
US61/034,464 2008-03-06
US4488608P 2008-04-14 2008-04-14
US61/044,886 2008-04-14

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2010520118A Division JP2010535232A (ja) 2007-07-30 2008-07-28 Ｍｅｋの阻害剤としての多形体を含む、ｎ−（アリールアミノ）スルホンアミドの誘導体、および組成物、使用方法、ならびにその調製方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017018477A Division JP2017125021A (ja) 2007-07-30 2017-02-03 Ｍｅｋの阻害剤としての多形体を含む、ｎ−（アリールアミノ）スルホンアミドの誘導体、および組成物、使用方法、ならびにその調製方法

Publications (3)

Publication Number Publication Date
JP2015078199A JP2015078199A (ja) 2015-04-23
JP2015078199A5 true JP2015078199A5 (enExample) 2016-05-26
JP6309880B2 JP6309880B2 (ja) 2018-04-11

Family

ID=40304796

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010520118A Pending JP2010535232A (ja) 2007-07-30 2008-07-28 Ｍｅｋの阻害剤としての多形体を含む、ｎ−（アリールアミノ）スルホンアミドの誘導体、および組成物、使用方法、ならびにその調製方法
JP2014231450A Expired - Fee Related JP6309880B2 (ja) 2007-07-30 2014-11-14 Ｍｅｋの阻害剤としての多形体を含む、ｎ−（アリールアミノ）スルホンアミドの誘導体、および組成物、使用方法、ならびにその調製方法
JP2017018477A Pending JP2017125021A (ja) 2007-07-30 2017-02-03 Ｍｅｋの阻害剤としての多形体を含む、ｎ−（アリールアミノ）スルホンアミドの誘導体、および組成物、使用方法、ならびにその調製方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2010520118A Pending JP2010535232A (ja) 2007-07-30 2008-07-28 Ｍｅｋの阻害剤としての多形体を含む、ｎ−（アリールアミノ）スルホンアミドの誘導体、および組成物、使用方法、ならびにその調製方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017018477A Pending JP2017125021A (ja) 2007-07-30 2017-02-03 Ｍｅｋの阻害剤としての多形体を含む、ｎ−（アリールアミノ）スルホンアミドの誘導体、および組成物、使用方法、ならびにその調製方法

Country Status (22)

Country Link
EP (1) EP2184984A4 (enExample)
JP (3) JP2010535232A (enExample)
KR (3) KR20140098185A (enExample)
CN (2) CN103479604B (enExample)
AP (1) AP2817A (enExample)
AU (2) AU2008282338B2 (enExample)
BR (1) BRPI0815659A2 (enExample)
CA (1) CA2693390C (enExample)
CO (1) CO6470808A2 (enExample)
CR (1) CR11244A (enExample)
DO (1) DOP2010000045A (enExample)
EA (2) EA032294B1 (enExample)
EC (1) ECSP109910A (enExample)
HN (1) HN2010000203A (enExample)
IL (1) IL203296A (enExample)
MA (1) MA31881B1 (enExample)
MX (1) MX2010001244A (enExample)
NZ (1) NZ582929A (enExample)
PH (1) PH12015501914A1 (enExample)
SV (1) SV2010003469A (enExample)
TN (1) TN2010000049A1 (enExample)
WO (1) WO2009018233A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
CN102131771A (zh) * 2008-04-14 2011-07-20 阿迪生物科学公司 组合物及其制备和使用方法
CN102143943B (zh) * 2008-09-09 2014-03-12 弗·哈夫曼-拉罗切有限公司 酰基磺酰胺的多晶型物
EP2331136B1 (en) 2008-09-26 2018-01-10 OncoMed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
UY32486A (es) * 2009-03-11 2010-10-29 Ardea Biosciences Inc Tratamiento del cáncer de páncreas
MA33091B1 (fr) * 2009-03-11 2012-03-01 Ardea Biosciences Inc Combinaisons pharmaceutiques comprenant rdea119/bay 869766 pour le traitement de cancers specifiques
CA2814617C (en) 2009-10-13 2017-12-19 Allostem Therapeutics Llc Novel mek inhibitors, useful in the treatment of diseases
US8962606B2 (en) * 2009-10-21 2015-02-24 Bayer Intellectual Property Gmbh Substituted benzosulphonamides
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
CN102020651B (zh) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-芳基氨基吡啶酮甲酰胺mek抑制剂
CN102649773A (zh) * 2011-02-23 2012-08-29 苏州波锐生物医药科技有限公司 氨基芳香烃类化合物及其在制备抗恶性肿瘤药物中的用途
BR112013027448A2 (pt) * 2011-04-28 2020-09-01 Sloan-Kettering Institute For Cancer Research terapia de combinação com hsp90
UA113850C2 (xx) * 2011-05-27 2017-03-27 Хіральний синтез n-{3,4-дифтор-2-$(2-фтор-4-йодфеніл)аміно]-6-метоксифеніл}-1-$2,3-дигідроксипропіл]циклопропансульфонамідів
WO2013086260A2 (en) * 2011-12-09 2013-06-13 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of cancer
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
EP2854779A1 (en) * 2012-05-31 2015-04-08 Bayer Pharma Aktiengesellschaft Biomarkers for determining effective response of treatments of hepatocellular carcinoma (hcc) patients
MA37711A1 (fr) 2012-06-04 2017-05-31 Pharmacyclics Inc Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
CA3079071C (en) * 2012-10-19 2022-06-07 Array Biopharma Inc. Preparation of crystallized benzimidazole derivative as mek inhibitor and formulation comprising same
WO2014071183A1 (en) 2012-11-02 2014-05-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor
CN105073195A (zh) 2013-02-04 2015-11-18 昂科梅德制药有限公司 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测
EP2848246A1 (en) 2013-09-13 2015-03-18 Bayer Pharma Aktiengesellschaft Pharmaceutical compositions containing refametinib
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
US9629851B2 (en) 2013-09-20 2017-04-25 Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis ROCK in combination with MAPK pathway
US20170027940A1 (en) 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
US20170114323A1 (en) 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
JP6910946B2 (ja) 2014-08-25 2021-07-28 アイミューン セラピューティクス，インコーポレイテッド タマゴのタンパク質製剤およびその製造方法
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of proton tyrosine kinase inhibitor
SG11201911859QA (en) 2017-06-16 2020-01-30 Beta Pharma Inc Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
US20220380348A1 (en) * 2019-10-04 2022-12-01 Sumitomo Dainippon Pharma Oncology, Inc. Axl inhibitor formulations
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
EP4788839A1 (en) 2023-10-03 2026-08-12 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
CN118834328B (zh) * 2024-07-02 2025-09-16 江苏海洋大学 金属蛋白酶9抗原决定基印迹纳米颗粒的制备方法及应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162117A (en) * 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
JP2575590B2 (ja) * 1992-07-31 1997-01-29 塩野義製薬株式会社 トリアゾリルチオメチルチオセファロスポリン塩酸塩およびその水和物結晶ならびにそれらの製法
DE122007000045I2 (de) * 1992-08-25 2011-07-21 Gd Searle Llc Gd Searle Llc Darunavir oder pharmazeutisch vertragliche Salze, Hydroxyethylaminosulfonamide verwendbar als InhibiEster oder Prodrugs davon. toren retroviraler Proteasen.
US7115632B1 (en) * 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
JP2002534515A (ja) * 1999-01-13 2002-10-15 ワーナー−ランバート・カンパニー １−複素環置換されたジアリールアミン
GB0003224D0 (en) * 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
WO2003026574A2 (en) * 2001-09-24 2003-04-03 Au Jessie L-S Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy
EP1534262A1 (en) * 2002-07-17 2005-06-01 Titan Pharmaceuticals, Inc. Combination of chemotherapeutic drugs for increasing antitumor activity
UA82322C2 (uk) * 2002-07-30 2008-04-10 Центаріс Гмбх Застосування алкілфосфохолінів в комбінації з протипухлинними лікарськими засобами
JP2008535924A (ja) * 2005-04-12 2008-09-04 エラン ファーマ インターナショナル リミテッド ナノ粒子キナゾリン誘導体製剤
CA2605381A1 (en) * 2005-04-22 2006-11-02 Kissei Pharmaceutical Co., Ltd. Crystal polymorphism of 4'-{2-[(1s,2r)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethylamino]ethoxy}-3-isopropyl-3',5'-dimethylbiphenylcarboxylic acid hydrochloride
MX2008002114A (es) * 2005-07-21 2008-04-17 Ardea Biosciences Inc Inhibidores de n-(arilamino)-sulfonamida de mek.
JP2007099763A (ja) * 2005-09-08 2007-04-19 Toyama Chem Co Ltd ピペラシリンナトリウム・１水和物の新規な結晶及びその製造方法
TW200800150A (en) * 2005-12-21 2008-01-01 Organon Nv Compounds with medicinal effects due to interaction with the glucocorticoid receptor

Similar Documents

Publication Publication Date Title
JP2012153722A5 (enExample)
JP2018520205A5 (enExample)
CN115244058A (zh) 嘧啶并二环类衍生物、其制备方法及其在医药上的应用
JP2017507175A5 (enExample)
HRP20192209T1 (hr) Derivati benzofurana, postupci njihove pripreme i njihova uporaba u medicini
JP2019518766A5 (enExample)
JP2013525363A5 (enExample)
RU2016118753A (ru) Производные пиридилкетона, способ их получения и их фармацевтическое применение
HRP20180499T1 (hr) Spojevi i postupci za modulaciju kinaze, te odgovarajuće indikacije
RU2019101220A (ru) Кристаллические формы соединения триазолопиримидина
JP2013535491A5 (enExample)
JP2013525458A5 (enExample)
JP2016501221A5 (enExample)
JP2022071077A5 (enExample)
EP4691557A3 (en) Method of synthesizing thyroid hormone analogs and polymorphs thereof
HRP20140486T1 (hr) Postupci sinteze spojeva spirooksindola
ME02452B (me) Sredstva za induciranje apoptoze namijenjena liječenju raka i imunih i autoimunih bolesti
JP2023500483A5 (enExample)
RU2017136715A (ru) Производное имидазоизоиндола, способ его получения и медицинское применение
JP2016531108A5 (enExample)
JP2014534269A5 (enExample)
RU2016133731A (ru) Функционализованные соединения бензопирана и их применение
CA2796744A1 (en) Synthetic metabolites of fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
JP2013523680A5 (enExample)
JP2012509265A5 (enExample)